Supplementary Tables. Short *VADEMECUM* (besides conventional intra and postoperative care) for postcardiotomy extracorporeal life support implant, management, and weaning in adult patients

Indication		
	Failure to wean from CPB or cardio-circulatory compromise despite moderate/high dose of inotropes and vasoconstrictors as well as IABP for LV or BiV failure Failure to wean from CPB or	Consider V-A ECLS support (preferable peripheral with distal perfusion – central if severe peripheral vascular disease or aortic prosthesis graft) Consider OxyRVAD (if ventilatory
	cardio-circulatory compromise despite moderate/high dose of inotropes and vasoconstrictors for isolated RV failure	dysfunction coexists) or RVAD configuration (right atrium through femoral vein-pulmonary artery cannulation)
Monitoring		
	Blood lactate level	ECLS should be considered and applied prior to severe metabolic acidosis (lactate level <5-6 mmol/L)
	Venous cannula position (SVC) from the femoral vein in case of peripheral ECLS and adequate negative pressure (suction) at the ECLS pump	TEE or manual check
	Assessment of LV contractility, dilatation, signs of stasis ("smoke-like"), and extent of aortic valve opening, on full ECLS support	TEE -Consider immediate less-aggressive maneuvers, including IABP, or other direct or indirect LV venting modalities if no or very poor LV contraction, distension and signs of blood stasis as well as no aortic valve opening
	Check arterial pulsatility on full ECLS support	Consider IABP or other direct or indirect LV venting modalities with no or very low pulsatility
	Limb and cerebral perfusion	Front and bilateral limb perfusion
Bleeding control		
	Full Protamine and no Heparin administration Meticulous hemostasis and hemostatic glue around	
	central cannulation sites	
	Sternal closure	Consider cannula externalization techniques to enhance sternal closure

Table S1. Intraoperative implant, monitoring, and management

CPB: cardio-pulmonary bypass; V-A: veno-arterial; LV: left ventricular; BiV: biventricular; RV: right ventricular; RVAD: right ventricular assists device; ECLS: extracorporeal life support; SVC: superior vena cava; IABP: intra-aortic balloon pump; TEE: transesophageal echocardiography; NIRS: near-infrared spectroscopy

Table S2. Postoperative implant, monitoring and management

Indication		
	LV or BiV (including cardiac arrest) failure despite moderate/high dose of inotropes and vasoconstrictors as well as IABP	Consider V-A ECLS support (preferable peripheral with distal perfusion – central if severe peripheral vascular disease or aortic prosthesis graft)
	Isolated LV failure despite moderate/high dose of inotropes and vasoconstrictors	Consider alternative to ECLS system (transaortic or transatrial devices)
	Isolated RV failure despite high dose of inotropes and vasoconstrictors	Consider OxyRVAD (is ventilatory dysfunction coexists) or RVAD configuration (right atrium through femoral vein-pulmonary artery cannulation) or RV-related support devices (trans-pulmonary)
		Consider percutaneous right atrium and pulmonary artery cannulation for minimally invasive RV support
Monitoring and Management		
	Continuous assessment of arterial pulsatility extent on full ECLS support	Consider conservative approach first if feasible and sustainable (lower ECLS flow, vasodilation, higher PEEP, slightly higher dose of inotropes)
	Continuous assessment of arterial pulsatility extent on full ECLS support despite less- aggressive actions (see above)	Consider IABP if not present or other direct or indirect LV venting modalities if no or very poor LV contraction, distension and signs of blood stasis
		Do not accept a pulsatile blood pressure (or protracted aortic valve closure) for more than 3-4 hours – LV unloading strategies to be implemented
	Chest X-ray	Daily or on-demand evaluation of lung stasis
	Anticoagulation and blood- element monitoring	No anticoagulation should be considered if postoperative bleeding (>50 cc/hour) is present, for at least 24-48 hours with ECLS flow >3 to 3.5 L/min.
		Platelet, free hemoglobin, d-dimer levels must be serially monitored
		Consider heparin-induced thrombocytopenia in the presence of excessive and refractory platelet consumption
	Blood lactate levels	Adjust ECLS flow according to blood level trends.
		Serial lactate level monitoring should be carried out to evaluate the efficacy of end-organ perfusion

	If blood level trends do not improve
	despite high ECLS flow (check LV
	unloading), consider bowel ischemia and
	annly appropriate diagnostic assessment
	(CT)
Cardiac enzyme levels	Cardiac injury extent must be closely
	monitored and follow cardiac recovery or
	persistent/new injury
Liver function	Liver function must be closely monitor,
	particularly in the presence of RV failure to
	assess the trends of support efficacy
Renal function	Diuresis and creatinine levels should be
	monitored and used to timely establish
	external replacement (CRRT) in case of
	acute dysfunction
Fluid balance	Excessive fluid overload should be
	removed as soon as the hemodynamic
	condition and ECLS performance allow,
	also with CRRT in case of limited
	spontaneous or stimulated renal response
Adequate negative pressure	Consider additional cannula (SVC or
(suction) at the ECLS pump	contra-latera femoral vein) in case of high
and flow must be monitored	negative pressure on venous cannula (also
	after position check or repositioning) and
	adequate filling
Serial TEE assessment of LV	Consider IABP or other direct or indirect LV
contractility, dilatation, signs	venting modalities if no or very poor LV
of stasis ("smoke-like"), extent	contraction, distension and signs of blood
of aortic valve opening as well	stasis
as left cardiac chambers on	
full ECLS support	
	Consider frequent TEE monitoring in the
	presence of mechanical valve prosthesis
Limb and cerebral perfusion	Front and bilateral limb perfusion
 monitoring	monitoring with NIRS
	Serial and close monitoring of cannulated
 	limb perfusion adequacy
	Consider distal angiography or surgical
	revision of the cannulated limb in case of
	ischemia if distal perfusion is already in
	place
	Consider cannulation of the contra-lateral
	limb (with distal perfusion) or axillary
	artery or ascending aorta cannulation if
	ischemia occurs at the cannulate limb
 	(with distal perfusion)
Right and left arm oximetry	Assessment of potential differential
	oxygenation ("Harlequin syndrome")
	Consider Hybrid ECLS configuration
	(outflow cannula in SVC) in case of high
	differential oxygenation or upper torque
	desaturation

СТ	Consider brain CT in case of clinical (pupil
	asymmetry or no light reaction, seizures)
	for neurologic complication suspicion
EEG	Consider EEG in case of clinical (pupil
	asymmetry or no light reaction, seizures)
	for neurologic complication suspicion
Brain-related blood markers	Assessment of S-100 or enolase might be
	considered to monitor brain integrity
Duration and weaning	Weaning trials should start as signs of
	cardiac recovery is observed
	Weaning should be gradual with at least 24
	hours of observation
	Weaning should be achieved in 5-7 days, if
	not, consider escalation of support or
	treatment if suitable candidate
	Prolonged ECLS support should be
	expected in patients with myocarditis-like
	status

CPB: cardio-pulmonary bypass; V-A: veno-arterial; LV: left ventricular; BiV: biventricular; RV: right ventricular; RVAD: right ventricular assist device; ECLS: extracorporeal life support; SVC: superior vena cava; PEEP: positive end-expiratory pressure; IABP; intra-aortic balloon pump; TEE: transesophageal echocardiography; CT: computed tomography; CRRT: continuous renal replacement therapy; NIRS: near infra-red spectroscopy; EEG: electro-encephalography

Table S3. Weaning or transition from extracorporeal life support in the presence of left/biventricular or isolated right ventricular failure.

From V-A ECLS		
	Stable hemodynamic conditions for at least 24 hours	
	Mean arterial pressure >60 mmHg in the absence or low	
	vasopressors/inotropes	
	Low arterial lactates (<2 mmol/L)	
	PaO_2 /FiO ₂ >100 mmHg with ECLS FiO ₂ <21% and FiO ₂ 40% at mechanical ventilator	
	Aortic-flow velocity time integration (VTI) >10-12 cm at ECLS flow of 1-1.5 L/min	
	Left ventricular ejection fraction >20-25%	
	Doppler lateral mitral annulus peak systolic velocity ≥6 cm/sec	
	LV and RV adequate contractile response to volume challenge	
	Venous and arterial patency and lack of thrombi should be checked at after decannulation	
	Use of other temporary assist device, like trans-aortic suction device, may be used to enhance ECLS weaning	
	Transition to VAD if hemodynamic stabilization achieved, with expected high mortality, however, in the presence of liver dysfunction, inflammatory status, and obesity	
From OxyRVAD ECLS (isolated RV support)		
	No sweep gas for at least 2 hours to the oxygenator and maintained acceptable systemic arterial O2 saturation (>90%) with normal respiratory parameters	
	Stable hemodynamics with low doses of inotropes for at least 24 hours	
	Weaning trial should parallel prophylactic inotropic infusion (Levosimendan)	
	No signs of liver (transaminase increase) or renal (oliguria, anuria) stasis or evidence of steady and/or marked decrease	
	TAPSE >10 mm with ECLS flow at 1-1.5 L/min	
	Off-pump Long-axis/short-axis ratio <0.55	
	Lack of thrombi at the pulmonary artery level should be checked at after decannulation	

V-A: veno-arterial; ECLS: extracorporeal life support; RV: right ventricle; TAPSE: tricuspid annular plane systolic excursion; LVAD: left ventricular assists device; OxyRVAD: right ventricular assist device with oxygenator

Table S4. Type of hybrid ECLS configurations (according to ELSO nomenclature) (Broman LM, Taccone FS, Lorusso R et al. Crit Care 2019;23:36)

Type of configuration	Cannula/catheter/device position
Isolated ECLS – peripheral	
V _f -A _f V _j	Femoral vein – femoral artery/jugular vein
V _f V _j -A _f	Femoral vein/jugular vein – femoral artery
V _f -AsV _j	Femoral vein – subclavian artery/jugular vein
V _f V _j -As	Femoral vein/jugular vein – femoral artery
V _f V _p -A _f	Femoral vein/pulmonary artery – femoral artery
(dI)Va-A _f Vp	Double-lumen right atrium – femoral artery/pulmonary artery
V _f V _p -As	Femoral vein/pulmonary artery (single-lumen) – femoral artery
V _f -As/V _p	Femoral vein– femoral artery/pulmonary artery (single-lumen)
(dl)Va-AsVp	Double-lumen right atrium – femoral artery/pulmonary artery
(dl)V _a V _p -A _f	Double-lumen right atrium/pulmonary artery – femoral artery
(dl)V _a V _p -A _s	Double-lumen right atrium/pulmonary artery – subclavian artery
(dl) <u>V_{svc}V_{ivc}</u> -A _f V _a	Double-lumen superior/inferior vena cava – femoral artery/right atrium
$(dI)\underline{V_{svc}}\underline{V_{ivc}}\underline{V_a}-A_f$	Double-lumen superior/inferior vena cava/right atrium – femoral artery
Isolated ECLS - central	
V _a -A _a V _j	Right atrium-ascending aorta/jugular vein
(dl)V _p -A _a	Double-lumen pulmonary artery – aorta
(dl)Va-Aa	Double-lumen right atrium – aorta
V _a V _j -A _a	Right atrium/right jugular vein – aorta
V _a V _f -A _a	Right atrium/femoral vein – aorta
ECLS [conventional one drainage and one perfusion cannulas or hybrid (see above)] + combined catheters/devices	
Venting catheter in LV	LV apex – transaortic catheter – transmitral catheter
Venting catheter in LA	Trans-septal – superior right pulmonary vein
Venting device in PA	Transpulmonary catheter
IABP	Transfemoral
Impella	Transfemoral – transaortic – trans-subclavian suction device
TandemHeart	Transfemoral vein
PulseCath	Transaortic suction device

The "-" stands for the oxygenator position between drainage and perfusion LV: left ventricle; LA: left atrium; PA: pulmonary artery